Viral Determinants of Acute COVID-19 Symptoms in a Nonhospitalized Adult Population in the Pre-Omicron Era.

Autor: Goldberg SA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA., Lu S; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA., Garcia-Knight M; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA., Davidson MC; School of Medicine, University of California, San Francisco, San Francisco, California, USA., Tassetto M; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA., Anglin K; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA., Pineda-Ramirez J; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA., Chen JY; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA., Rugart PR; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA., Mathur S; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA., Forman CA; College of Medicine, Drexel University, Philadelphia, Pennsylvania, USA., Donohue KC; School of Medicine, University of California, San Francisco, San Francisco, California, USA., Abedi GR; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Saydah S; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Briggs-Hagen M; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Midgley CM; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Andino R; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA., Peluso MJ; Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, San Francisco, California, USA., Glidden DV; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA., Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA., Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.; F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.; Division of Hospital Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2023 Jul 24; Vol. 10 (8), pp. ofad396. Date of Electronic Publication: 2023 Jul 24 (Print Publication: 2023).
DOI: 10.1093/ofid/ofad396
Abstrakt: Background: The influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA level and presence of infectious virus on symptom occurrence is poorly understood, particularly among nonhospitalized individuals.
Methods: The study included 85 nonhospitalized, symptomatic adults, who were enrolled from September 2020 to November 2021. Data from a longitudinal cohort studied over 28 days was used to analyze the association of individual symptoms with SARS-CoV-2 viral RNA load, or the presence or level of infectious (culturable) virus. Presence of infectious virus and viral RNA load were assessed daily, depending on specimen availability, and amount of infectious virus was assessed on the day of maximum RNA load. Participants were surveyed for the start and end dates of 31 symptoms at enrollment and at days 9, 14, 21, and 28; daily symptom presence was determined analytically. We describe symptoms and investigate their possible association with viral determinants through a series of single or pooled (multiple days across acute period) cross-sectional analyses.
Results: There was an association between viral RNA load and the same-day presence of many individual symptoms. Additionally, individuals with infectious virus were more than three times as likely to have a concurrent fever than individuals without infectious virus, and more than two times as likely to have concurrent myalgia, chills, headache, or sore throat.
Conclusions: We found evidence to support the association of viral RNA load and infectious virus on some, but not all symptoms. Fever was most strongly associated with the presence of infectious virus; this may support the potential for symptom-based isolation guidance for COVID-19.
Competing Interests: Potential conflicts of interest. M. J. P. reports consulting for Gilead Sciences and AstraZeneca, outside the submitted work. All other authors report no potential conflicts.
(Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje